Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
NCT00288522
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class
Conditions
Thyroid-Associated Ophthalmopathy
Interventions
DRUG:
Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
Sponsor
Ipsen